Araştırma Makalesi

Antibody Identity in Suspected Covid-19 Patients and Other Parameters

Cilt: 5 Sayı: 1 28 Şubat 2021
PDF İndir
TR EN

Antibody Identity in Suspected Covid-19 Patients and Other Parameters

Öz

Aim: This study aimed to report laboratory findings of PCR and antibody research in suspect Covid-19 patients.
Materials and Methods: A total of 4206 patients with suspected Covid-19 and respiratory tract infection and 232 patients with mild clinical presentations such as cold who were admitted in hospitals were included in the study. After clinical examinations and radiological screenings, PCR tests of 4206 patients and antibody surveys of the 232 patients who were not hospitalized due to having only mild symptoms were carried out. For antibody detection, the plasmas of the EDTA-containing blood samples that were collected from the patients who were treated for Covid-19 and patients who were not treated due to having no symptoms or mild symptoms were separated and analyzed. The ‘Coronavirus disease IgM/IgG Rapid Test were used for the detection of antibodies. Antibody screenings were repeated three times 10, 17 and 24 days after the patients were diagnosed with Covid-19.
Results: The suspected Covid-19 were aged between 27 and 87 years and 2004 of the individuals were female (48%) and 2202 of the individuals were male (52%). Of 4206 plasma samples, 276 samples (6.56%) were RT-PCR-positive. Of the patients who had a positive PCR and were treated for Covid-19, 104 patients (37.68%) were female and 172 patients (62.32%) were male.
Conclusion: It is observed that death rates due to Covid-19 are more moderate in patients living in a cold climate and showing flu symptoms several times a year. Our study is in the form of some of the data of our region in order to shed light on future studies on this subject.

Anahtar Kelimeler

Kaynakça

  1. 1. Cui J, Li F, Shi Z.L. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol, 2019: 17;181–192.
  2. 2. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA, 2020; 24. doi:10.1001/jama.2020. 2648
  3. 3. Kolb A.F, Hegyi A, Siddell S.G. Identification of residues critical for the human coronavirus 229E receptor function of human aminopeptidase N. J. Gen. Virol, 1997: 78; 2795–2802.
  4. 4. Li W, Sui J, Huang I.C, Kuhn J.H, Radoshitzky S.R, Marasco W.A, Choe H, Farzan M. The S proteins of human coronavirus NL63 and severe acute respiratory syndrome coronavirus bind overlapping regions of ACE2. Virology, 2007: 367; 367–374.
  5. 5. Hulswit R.J.G, Lang Y, Bakkers M.J.G, Li W, Li Z, Schouten A, Ophorst B, van Kuppeveld F.J, BoonsG.J, Bosch B.J. HumancoronavirusesOC43andHKU1bindto9-O acetylated sialic acids via a conserved receptor-binding site in spike protein domain A. Proc. Nat. Acad. Sci, 2019: 116; 2681–2690.
  6. 6. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit Care, 2020: 24(1); 108.
  7. 7. Coronavirus 2019-nCoV, CSSE. Coronavirus 2019-nCoV Global Cases by Johns Hopkins CSSE. (Available from: https://gisanddata.maps.arcgis.com/apps/opsdashboard/index. html#/bda7594740fd40299423467b48e9ecf6) (accession date 15.11.2020)
  8. 8. Xu X.T, Chen P, Wang J.F, Feng J.N, Zhou H, Li X, Zhong W, Hao P. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci.China Life Sci, 2020: 63(3); 457-460.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Klinik Tıp Bilimleri

Bölüm

Araştırma Makalesi

Yayımlanma Tarihi

28 Şubat 2021

Gönderilme Tarihi

15 Ocak 2021

Kabul Tarihi

1 Şubat 2021

Yayımlandığı Sayı

Yıl 2021 Cilt: 5 Sayı: 1

Kaynak Göster

APA
Çelebi, Ö., Balkan Bozlak, Ç. E., İba Yılmaz, S., & Çelebi, D. (2021). Antibody Identity in Suspected Covid-19 Patients and Other Parameters. Balıkesir Medical Journal, 5(1), 9-17. https://doi.org/10.33716/bmedj.861895
AMA
1.Çelebi Ö, Balkan Bozlak ÇE, İba Yılmaz S, Çelebi D. Antibody Identity in Suspected Covid-19 Patients and Other Parameters. BMedJ. 2021;5(1):9-17. doi:10.33716/bmedj.861895
Chicago
Çelebi, Özgür, Çiğdem Eda Balkan Bozlak, Sibel İba Yılmaz, ve Demet Çelebi. 2021. “Antibody Identity in Suspected Covid-19 Patients and Other Parameters”. Balıkesir Medical Journal 5 (1): 9-17. https://doi.org/10.33716/bmedj.861895.
EndNote
Çelebi Ö, Balkan Bozlak ÇE, İba Yılmaz S, Çelebi D (01 Şubat 2021) Antibody Identity in Suspected Covid-19 Patients and Other Parameters. Balıkesir Medical Journal 5 1 9–17.
IEEE
[1]Ö. Çelebi, Ç. E. Balkan Bozlak, S. İba Yılmaz, ve D. Çelebi, “Antibody Identity in Suspected Covid-19 Patients and Other Parameters”, BMedJ, c. 5, sy 1, ss. 9–17, Şub. 2021, doi: 10.33716/bmedj.861895.
ISNAD
Çelebi, Özgür - Balkan Bozlak, Çiğdem Eda - İba Yılmaz, Sibel - Çelebi, Demet. “Antibody Identity in Suspected Covid-19 Patients and Other Parameters”. Balıkesir Medical Journal 5/1 (01 Şubat 2021): 9-17. https://doi.org/10.33716/bmedj.861895.
JAMA
1.Çelebi Ö, Balkan Bozlak ÇE, İba Yılmaz S, Çelebi D. Antibody Identity in Suspected Covid-19 Patients and Other Parameters. BMedJ. 2021;5:9–17.
MLA
Çelebi, Özgür, vd. “Antibody Identity in Suspected Covid-19 Patients and Other Parameters”. Balıkesir Medical Journal, c. 5, sy 1, Şubat 2021, ss. 9-17, doi:10.33716/bmedj.861895.
Vancouver
1.Özgür Çelebi, Çiğdem Eda Balkan Bozlak, Sibel İba Yılmaz, Demet Çelebi. Antibody Identity in Suspected Covid-19 Patients and Other Parameters. BMedJ. 01 Şubat 2021;5(1):9-17. doi:10.33716/bmedj.861895